1. Scrip
  2. >>Business

GSK Prunes The Pipeline To Make Way For The New

 
• By Jessica Merrill

CEO Emma Walmsley has vowed to be more decisive when it comes to progressing drugs to late-stage development. The company terminated five programs, including several in respiratory disease to prioritize other assets and business development.

SC1810_Pruning_625931555_1200.jpg

GlaxoSmithKline PLC CEO Emma Walmsley told investors she is sticking to her pledge to remove bureaucracy from the drug development process and prioritize investment in high-value candidates, during the firm's third quarter earnings call Oct. 31.

"We have clearly said we will be more decisive with our pipeline and, this quarter, we've also decided to terminate five development programs," she said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.